
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is well-positioned to capitalize on this unmet need through its innovative approach to targeting STAT3 and potential for successful combination therapies. Their strong pipeline, strategic partnerships, and successful preclinical results bode well for their future success and potential to make a significant impact on improving patients' lives. With a clear focus and promising developments ahead, Tvardi Therapeutics has the potential to see significant growth and success in the biopharmaceutical market.
Bears say
Tvardi Therapeutics is currently facing a number of fundamental challenges that may hinder the success of its pipeline, including regulatory uncertainty, a lack of approved products, and potential challenges in drug delivery for its first-generation direct STAT3 inhibitor, TTI-101. With the recent setback in the REVERT LIVER CANCER trial and the need for additional dosing and clinical data, there is significant risk associated with the company's lead program, TTI-101. Based on current financials and expected developments, we believe that the stock is overvalued and may continue to face significant downward pressure.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares